NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jun 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
5/8 — Partial
CLARINEX (desloratadine) by Merck & Co. is 1 -receptor histamine antagonist activity. Approved for seasonal allergic rhinitis, chronic idiopathic urticaria. First approved in 2002.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Clarinex (desloratadine) is an oral H1-receptor histamine antagonist indicated for seasonal allergic rhinitis and chronic idiopathic urticaria. It works by blocking histamine receptors and inhibiting histamine release from mast cells, with minimal blood-brain barrier penetration to reduce sedation. Available as an orally disintegrating tablet, it offers convenient dosing for allergy sufferers.
$0.289MPart D
LOE ApproachingDeclining
Minimal commercial growth expected as product approaches loss of exclusivity; brand team likely focused on defensive strategies and possible line extensions rather than expansion.
Mechanism of Action
1 -receptor histamine antagonist activity. Receptor binding data indicate that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a…
Indications (2)
Worked on CLARINEX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.